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Extra-pancreatic metastasis is a difficult problem for surgical intervention in pancreatic cancer. CXC chemokine receptor 4 (CXCR4)
was considered to have an important role in this process. We hypothesized it may contribute to the pancreatic cancer progression
through influencing canonical Wnt pathway. The purpose of this study was to examine the functional role of CXCR4 in the
progression of pancreatic cancers and explore the possible mechanism. To this end, the relation between CXCR4 and clinical
characteristics was analysed. shRNA against CXCR4 was applied to disrupt the SDF-1/CXCR4 signal transduction pathways in
pancreatic cancer cell lines. Our results showed that overall survival in the case of patients positive for CXCR4 expression was
significantly lower than that in the case of patients negative for CXCR4 expression. Notably, in vitro studies we observed that the
abrogation of CXCR4 could obviously influence the pancreatic cancer cell phenotype including cell proliferation, colony formation,
cell invasion and also inhibit the TOPflash activity. In addition, Wnt target genes and mesenchymal markers such as Vimentin and Slug
were also inhibited in CXCR4 knockdown cells. Collectively, these data reported here demonstrate CXCR4 could modulate the
canonical Wnt pathway and perhaps be a promising therapeutic target for pancreatic cancer progression.
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Pancreatic ductal adenocarcinoma (PDA) is the fourth leading
cause of cancer deaths in Western countries (Jemal et al, 2007). It
represents a disease with a poor prognosis, and the survival has
been further associated with tumours that locally extended beyond
the pancreas and metastasize in the regional lymph nodes
(Butturini et al, 2008). The reasons behind the peculiar metastatic
tropism are largely unknown. It appears that some understanding
of the possible mechanism underlying the progression of
pancreatic cancer is required to improve the clinical outcome.
Metastasis progress is a complex mechanism in which many
factors can potentially influence tumour dissemination (Murphy,
2001). Recently, the function of chemokines in the process of
cancer metastasis has attracted increased attention. Chemokines
and their receptors are critical mediators of cell migration during
routine immune surveillance, inflammation, and development
(Singh et al, 2007; O’Hayre et al, 2008). One of the best studied
chemokine receptors is CXCR4, primarily because of its role as a
coreceptor for HIV entry as well as its ability to mediate the
metastasis of a variety of cancers (Balkwill, 2004a). CXCR4
selectively binds the CXC chemokine stromal cell-derived factor
1 (SDF-1, or CXCL12), which has been found to play an important
role in tumorigenesis, proliferation, metastasis, and angiogenesis
in cancers (Burger and Kipps, 2006). The expression of CXCR4,
confirmed in more than 23 solid cancers, was upregulated on the
surface of tumour cells of epithelial origin (Balkwill, 2004b).
Moreover, CXCR4-positive tumour cells could migrate toward
distant organs in response to SDF-1 gradient. With the inhibition
of CXCR4, the growth and invasion could be impaired in some
type of cancer cells (Muller et al, 2001; Ottaiano et al, 2005).
Involvement of SDF-1/CXCR4 was reported during prostate
cancer, ovarian cancer, colorectal cancer, hepatocellular carcinoma
as well as pancreatic cancer (Hart et al, 2005; Jiang et al, 2006;
Schimanski et al, 2006; Yoshitake et al, 2008). It was reported that
CXCR4 was expressed at higher levels in pancreatic cancer cells
and could influence the clinical outcome of PDA patients (Wehler
et al, 2006; Billadeau et al, 2006). The microarray results showed
that pancreatic juice from pancreatic cancer patients contained
increased RNA level of the CXCR4 gene (Rogers et al, 2006).
Recent evidence has shown that multiple factors could enhance
CXCR4 expression, such as hypoxia-inducible factor 1, vascular
endothelial growth factor, activation of nuclear factor kappa B and
hepatocyte growth factor (Bachelder et al, 2002; Staller et al, 2003;
Helbig et al, 2003; Matteucci et al, 2005). However, the relative
mechanism underlying the downstream modulation function of
SDF-1/CXCR4 on pancreatic cancer progression is poorly under-
stood.
The Wnt/b-catenin canonical Wnt-signalling pathway has been
implicated in tumorigenesis at several sites, including the colon,
rectum, breast, and liver (Peifer and Polakis, 2000). Its central
component, namely, b-catenin, plays a critical role in this process
(Nelson and Nusse, 2004). Firstly, b-catenin is phosphorylated in
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sthe inactive phase of Wnt pathway with the absence of Wnt or the
presence of Wnt inhibitors. The aberrant secretion of Wnt factors
or the presence of APC mutation could lead to abnormal b-catenin
activation which in turn leads to the activation of Wnt signalling
and the process of epithelial–mesenchymal transition (EMT)
(Brabletz et al, 2001; Reya and Clevers, 2005). A number of
downstream target genes of Wnt/b-catenin signalling have been
reported, which play critical roles in carcinogenesis by affecting
cell growth, cell cycling, cell survival and invasion (www.stanford.
edu/~rnusse/wntwindow.html). The mutation of APC or
b-catenin which is commonly found in other gastrointestinal
cancer could not be always detected in PDA (Abraham et al, 2002).
Aberrant activation of Wnt signalling is a significant feature of
human pancreatic adenocarcinoma, as revealed by aberrant
b-catenin expression in a significant fraction (30–65%) of tumours
(Lowy et al, 2003; Al-Aynati et al, 2004; Zeng et al, 2006).
Based on previous research on the central role of CXCR4 and the
canonical Wnt pathway, we hypothesized that CXCR4 plays a role
in the pancreatic cancer metastasis through the Wnt/b-catenin
pathway (Wang and Ma, 2007). The aim of this study was to
determine the role of CXCR4 in pancreatic cancers and elucidate
the underlying mechanism.
MATERIALS AND METHODS
Cell line and culture conditions
Human pancreatic cancer cell lines (PC-2, PC-3, Miapaca-2, Bxpc-3,
and Panc-1) were stored in the Department of Hepatobiliary
Surgery, the First Affiliated Hospital of Xi’an Jiaotong University.
The cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% FBS (Invitrogen, Carlsbad, CA, USA),
penicillin (100Uml
 1) and streptomycin (0.1mgml
 1).
Immunohistochemistry
Samples including 48 pancreatic carcinoma and 8 normal pancreas
specimen were obtained from the Department of Hepatobiliary
Surgery, the First Affiliated Hospital of Xi’an Jiaotong University.
Immunohistochemical staining for CXCR4 were performed using
the SABC kit (Maxim, Fuzhou, China) according to the manu-
facturer’s instruction. Primary antibody for CXCR4 (1:50) was
obtained from eBioscience (San Diego, CA, USA) and incubation
overnight at 41C. For the evaluation of protein expression,
the staining intensity was graded as 0 (negative), 1 (weak),
2 (medium), or 3 (strong). The extent of staining was graded as
0 (0%), 1 (1–10%), 2 (11–50%), 3 (51–80%) and 4 (481%)
according to the percentage of positive staining area relative to the
total tumour area. The final immunohistochemical staining score
was obtained by multiplying the intensity and the extent of
staining (Leo et al, 2006).
CXCR4 shRNA expression vector construct
The human CXCR4 gene sequence (Genbank accession, no.
NM_003467) was analysed for a potential siRNA target with the
web-based siRNA target finder and design tool provided by
Genscript (Piscataway, NJ, USA) and Ambion (Applied Biosystems,
Austin, TX, USA) according to the manufacturer’s protocol.
The following shRNA insert sequence was synthesized: 50-gatcc
TGAGAAGCATGACGGACAAttcaagagaTTGTCCGTCATGCTTCTCA
ttttttggaaa-30 (target position: 301) and 50-gatccAGCGAGGTGGAC
ATTCATCttcaagagaGATGAATGTCCACCTCGCTttttttggaaa-30 (tar-
get position: 1093). As a negative control, a vector was also
designed, whose inserted sequence was 50-gatccTTCTCCGAA
CGTGTCACGTttcaagagaACGTGACACGTTCGGAGAAttttttggaaa-30,
which does not target any region in human genome. Sense and
antisense oligonucleotides were annealed. After digestion with
BamHI and HindIII, the fragments were inserted into the shRNA
expression vector pRNAT-U6.1/Neo (GenScript Corp., Piscataway,
NJ, USA) and confirmed by plasmid sequencing.
Stable transfection of CXCR4 shRNA expression vector
In a 24-well plate, 5 10
4 cells were plated per well 1 day before
transfection. Transfection was performed using the lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s suggestion. At 24h after transfection, the cell solution was
diluted at 1:10 and regenerated. In the 10% DMEM culture,
400mgml
 1 G418 (Invitrogen, Carlsbad, CA, USA) was added for
selection after the cells adhered to the plate. A limited dilution was
used in a 96-well plate for repeated colony selection. After 14 days,
G418 (200mgml
 1) was added for the future stable transfected
cell culture.
Quantitative real-time polymerase chain reaction
(QT–PCR) to detect mRNA expression
To extract total RNA, 2 10
5 cells were harvested with the Trizol
Reagent (Invitrogen, Carlsbad, CA, USA). cDNA synthesis was
conducted as followed with the SYBR
s ExScript
t RT–PCR kit
(Takara Biotechnology Co. Ltd., Dalian, China) according to
manufacturer’s instruction: 500ng total RNA was mixed with 2ml
of 5  ExScriptt RTase buffer, 0.5ml of dNTP mixture, 0.5mlo f
random hexamers, 0.25ml of ExScriptt Rtase, and 0.25ml of RNase
inhibitor in a total volume of 10ml. The reactions were performed
at 421C for 12min, followed by inactivation of the reverse
transcriptase at 951C for 2min. The cDNA was stored at  201C.
QT–PCR was performed on an ABI PRISM
s 7300 Sequence
Detection System (Applied Biosystems, Foster City, CA, USA) with
the SYBR Green Master Mix. The final reaction volume was 25ml
and contained 12.5ml2  SYBR
s Premix Ex Taqt, 1.0ml of each
primer (10mM), 0.5ml5 0  ROX reference dye, and 1.0ml cDNA.
The cycling conditions were as follows: initial denaturation at 951C
for 10min, followed by 40 cycles of 951C for 15s, and 601C for 60s.
Each measurement was performed in triplicate, and no-template
controls were included for each assay. In each QT–PCR,
a dissociation curve analysis was conducted. GAPDH was applied
as the internal housekeeping gene control. Relative gene expres-
sion was calculated using the 2 DDCt method (Livak and
Schmittgen, 2001).
Cell proliferation assay
Cells were seeded in a 96-well plate at a concentration of 5 10
3
per well a day before the experiment. 3-[4,5-Dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT, 0.5mgml
 1, Sigma-
Aldrich, St. Louis, MO, USA) was added to each well at 1, 2, 3, 4,
5 days after seeding. Generally, cells were cultured at 371C for 4h,
and then 150ml DMSO was added. The absorption value was
measured at a wavelength of 490nm.
Flow cytometric analysis
Before flow cytometric analysis, 1 10
6 cells were collected,
washed two times with PBS, and fixed with ice-cold 70% ethanol
for 24h at 41C. The fixed cells were stained with propidium iodide
(Beckman Coulter, Miami FL, USA). After incubation for 30m at
371C, the samples were analysed by a Flow Cytometry. Cell cycle
analysis of DNA histograms was performed with the MultiCycle
software.
Soft agar colony formation assay
In six-well plates, each well contained a bottom layer of 1%
agarose, a middle layer of 0.5% agarose which included 7.5 10
3
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scells, and a top layer of medium. The medium at the top layer was
changed on every sixth day. After 14 days, cells were stained with
Giemsa solution (Gibco-BRL, Gaithersburg, MD, USA) and
counted by Quantityone analysis software (BioRad Inc., Hercules,
CA, USA).
Protein extraction and western blotting
Total protein was isolated from 1 10
7 cells with 200ml of ice-cold
lysis buffer containing 1% Nonidet P-40 (NP-40), 50mmoll
 1 Tris
(pH 7.4), 150mmoll
 1 NaCl, 0.1% sodium dodecyl sulfate (SDS),
0.5% deoxycholate, 200mgml
 1 phenylmethanesulfonyl fluoride
(PMSF), and 50mgml
 1 aprotinin. Insoluble materials were
removed by centrifugation at 15000g for 15min at 41C. The
concentration of the extracted protein was measured spectro-
photometrically with Coomassie G-250. Clarified protein lysates
(30–80mg) were electrophoretically resolved on a denaturing SDS-
polyacrylamide gel (8–12%), and electrotransferred onto nitro-
cellulose membranes. The membranes were initially blocked with
5% nonfat dry milk in Tris-buffered saline (TBS) for 2h and then
probed with primary antibodies against the specific protein and
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Figure 1 The expression of CXCR4 on pancreatic cancers. (A) immunohistochemistry staining of CXCR4 on normal pancreatic tissues (a) and
pancreatic cancer tissues (b–d)  200: negative expression (a), weak expression (b), moderate expression (c), strong expression (d); (B) Kaplan–Meier
curve showed that the median survival time of the CXCR4-positive and CXCR4-negative groups was 5.5 and 13.5 months; (C). Western blot analysis
revealed the CXCR4 expression for 5 pancreatic cancer cells (PC-2, PC-3, Miapaca-2, Bxpc-3, Panc-1). GAPDH was used as a loading control.
Table 1 The relation between CXCR4 expression and clinical
characteristics in PDA patients
Clinical pathologic variables CXCR4 median score P-value
Age
465 5.6 0.542
o65 4.4
Histology
Well 3.1
Moderate 4.9 0.062
Poor 5.5
Lymph node metastasis
Positive 6.1 0.012
Negative 3.0
TNM stage
I 1.7
II 3.8 0.005
III 5.4
IV 7.9
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sGAPDH (as loading control). After coincubation with the primary
antibodies at 41C overnight, the membranes were hybridised with
the secondary alkaline phosphatase-conjugated goat anti-rabbit
antibody (1:2000), goat anti-mouse antibodies (1:3000) (Kang-
chen, Shanghai, China) for 2h at room temperature. The
immunopositive bands were examined by an enhanced chemi-
luminescence (ECL) detection system (Amersham Bioscience,
Piscataway, NJ, USA) and the images were transferred onto an
X-ray film. The western blot was graded positive if the band of
interest was present at the expected molecular weight correspond-
ing to each marker protein. All analyses were done in duplicate.
Antibodies used in this study: CXCR4 (1:200) and MMP-9 (1:250)
(NeoMarkers, Fremont, CA, USA), Vimentin (1:200) and GAPDH
(1:400) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), P339-
CXCR4 antibody (1:200) was kindly provided by Professor
Joshua B. Rubin in Washington University School of Medicine at
St Louis.
b-Catenin/Tcf transcription reporter assay
Briefly, 1 10
5 cells were seeded per well in a 24-well plate before
transient transfection with the construct TOPflash or FOPflash
reporter plasmid (Millipore, Billerica, MA, USA). TOPflash
comprised three copies of the Tcf/Lef sites upstream of a
thymidine kinase (TK) promoter and the Firefly luciferase gene.
FOPflash comprised three mutated copies of Tcf/Lef sites and were
used as a control for measuring nonspecific activation of the
reporter. All transfections were performed using 0.8mg of TOPflash
or FOPflash plasmid and 2ml lipofectamine 2000. To normalise the
transfection efficiency in reporter assays, the cells were cotrans-
fected with 0.02mg of an internal control reporter plasmid,
containing Renilla reniformis luciferase driven by the TK
promoter. At 24h after TOPflash or FOPflash transfection, the
luciferase assay was performed with the Dual Luciferase Assay
System kit (Promega Corp., Madison, WI, USA). Relative luciferase
activity was reported as the fold induction after normalization for
transfection efficiency.
Matrigel invasion assay
An invasion assay was performed with a Millicell invasion chamber
(Millipore, Billerica, MA, USA). The 8mm pore inserts were coated
with 15mg of Matrigel (Becton Dickinson Labware, Bedford, MA,
USA). Normal culture medium with or without 100ngml
 1 SDF-1a
(R&D systems Inc., Minneapolis, MN, USA) was added at the
bottom chamber to induce the cancer cell lines. Cells (5 10
4) were
seeded in the top chamber. The Matrigel invasion chamber was
incubated for 20h in a humidified tissue culture incubator. Non-
invading cells were removed from the top of the Matrigel with a
cotton-tipped swab. Invading cells on the bottom surface of filter
were fixed in methanol and stained with Giemsa. Invasion ability
was determined by counting the stained cells.
Statistical analysis
All statistical analyses were performed using the SPSS13.0
software. The results were presented as means±s.d. of three
replicate assays. Differences between the groups were assessed by
the Student’s t-test or analysis of variance (ANOVA). Po0.05 was
considered to indicate statistical significance.
RESULTS
Association of CXCR4 expression level with pancreatic
cancers
Immunohistochemistry staining results showed that CXCR4
expression was detected not in the normal pancreatic cells but in
the cytoplasm of most pancreatic cancer cells. The representative
staining results are shown in Figure 1A. Different CXCR4
expression was observed between the non-metastasized and
metastasized cells, and observed among the tumour node
metastasis (TNM) stages (P¼0.012, 0.005, respectively) (Table 1).
The median survival time of the CXCR4-positive and CXCR4-
negative groups were 5.5 and 13.5 months, respectively (Po0.05)
(Figure 1B). Moreover, CXCR4 expression was highly expressed in
pancreatic cancer cell lines, especially Miapaca-2 (Figure 1C).
Establishment of stable CXCR4 knockdown
Knockdown of transcripts using shRNA is a powerful tool for
studying gene function. To study the long-term growth pattern of
tumour cells in vitro, we developed pRNAT-U6.1/Neo vectors
containing small hairpin constructs capable of generating 19
nucleotide duplex RNAi oligonucleotides. We succeeded in
obtaining stable shRNA vector-transfected cells termed
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Figure 2 Establishment of stable CXCR4 knockdown. (A) QT–PCR
analysis of CXCR4 expression after the transfection of different CXCR4
shRNA expression vectors: pRNAT-M1 (target position: 301), pRNAT-M2
(target position: 1093), pRNAT-MN (negative control) and Miapaca-2,
*Po0.05 compared with pRNAT-MN cells; (B) western blot with CXCR4
antibody for different transfected pancreatic cancer cells. GAPDH was
detected as a loading control; (C) Western blot showed the different
expressions of CXCR4, phosphorylated CXCR4 on Serine 339 (P339-
CXCR4) on transfected cells. GAPDH was detected as a loading control.
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spRNAT-M1 (target position: 301), pRNAT-M2 (target position:
1093), and pRNAT-MN (negative control vector). QT–PCR
analysis showed that compared with pRNAT-MN cells, the CXCR4
mRNA expression was inhibited up to 70% in CXCR4 shRNA-
transfected cell lines, particularly in pRNAT-M1 cells (Po0.05).
Compared with Miapaca-2 cells, approximately 20% decrease of
CXCR4 mRNA expression in pRNAT-MN cells was founded
(Figure 2A). Moreover, the CXCR4 protein level was also down-
regulated significantly in pRNAT-M1 cells than in pRNAT-MN
cells (Figure 2B). Notably, the decrease of CXCR4 phosphorylation
at serine 339 was observed in pRNAT-M1 cells. By band analysis,
the proportion of phosphorylated CXCR4 was also reduced in
pRNAT-M1 cells (Figure 2C).
Abrogation of CXCR4 inhibits cell proliferation, delays cell
cycle and decreases colony-forming ability
To confirm the effect of CXCR4 inhibition on cell growth, stable
transfectants with CXCR4 shRNA were cultured. MTT assay
showed that the pRNAT-M1 cells grew slower than pRNAT-MN
cells. On the fifty day after seeding, different growth was noticed
between pRNAT-M1 and pRNAT-MN cells (Po0.05). However,
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Figure 3 The influence of CXCR4 knockdown on the cell phenotype. (A) MTT assay was analysed for pRNAT-M1, pRNAT-MN, and Miapaca-2 on days 1,
2, 3, 4, and 5; (B) Distribution of cell cycle phases was demonstrated by flow cytometric analysis for pRNAT-M1 and pRNAT-MN; (C) Soft agar assay was
assessed to evaluate the cell colony formation ability. The count number of the colony was shown in the diagram; *Po0.05 compared with pRNAT-MN cells.
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sthere was no difference between Miapaca-2 cells and pRNAT-MN
cells (P40.05) (Figure 3A). According to the analysis of cell cycle
distribution by flow cytometry, we found a prolonged and
prominent delay in progression from G0 to G1 phase (51.23 vs
76.51%), a decrease at the S phase (41.16 vs 23.0%) and G2-M
phase (1.61 vs 0.39%). Moreover, sub-G1 apoptotic compartment
was also observed in pRNAT-M1 cells (Figure 3B). To explore the
effect of CXCR4 knockdown on tumorigenesis in vitro,w e
performed soft agar colony formation assay. It showed that the
colony formation by pRNAT-M1 cells was decreased than that by
pRNAT-MN cells (Po0.05) (Figure 3C).
CXCR4 knockdown inhibits Wnt activity, Wnt target gene
and invasion-related genes
As an important pathway for gastrointestinal cancer development,
the Wnt/b-catenin pathway and genes associated with cell
invasiveness were paid more attention. The b-catenin/Tcf
transcription reporter assay was recognised as an important
assessment method for evaluation of the Wnt pathway activity. As
TOPflash has three TCF-binding sites, it could be applied to
represent the activation of the Wnt pathway. Our data showed that
compared with the pRNAT-MN cells, the CXCR4 knockdown cells
exhibited a decreased TOPflash activity (Po0.05) and unchanged
FOPflash activity (Figure 4A). Moreover, QT–PCR analysis
showed that Wnt target genes such as CTNNB1, UPA, and CD44
were inhibited in pRNAT-M1 cells, but the expression of MYC and
CCND1 did not change (Figure 4B). At the same time, the
inhibition of CXCR4 resulted in decreased Slug, Vimentin and
MMP-9 expression (Po0.05) (Figure 4C).
CXCR4 knockdown decreases the invasion of pancreatic
cancer cells
The Matrigel invasion assay was performed to assess the
invasiveness of the cancer cells. Representative staining results
were shown at Figure 5A. The results showed that pRNAT-MN
cells were more invasive than pRNAT-M1 cells (Po0.05). After the
SDF-1 stimulation, pRNAT-MN cells showed an obvious increase
in invasiveness (Po0.05), but pRNAT-M1 cells demonstrated a
slight increase (Figure 5B).
DISCUSSION
The majority of PDA patients have locally advanced or metastatic
disease and thus are not candidates for surgical intervention
(Winter et al, 2006). The main cause is the extra-pancreatic
invasion and metastasis to the liver, lung or other tissues. Many
factors such as adhesion molecules, proteases, cytokines, and
chemokine are involved in this process. A complex network of
chemokine and chemokine receptors exist in tumour microenviron-
ment. The chemokine receptor CXCR4 is one of the representative
target genes (Schrader et al, 2002; Brand et al, 2005; Saur et al,
2005; Billadeau et al, 2006). In this study, we demonstrated that
overall survival in the case of patients positive for CXCR4
expression was significantly lower than that in the case of patients
negative for CXCR4 expression. Elevated CXCR4 expression was
correlated to an advanced cancer stage and metastasis. It is similar
to previous reports and also suggests that CXCR4 may be a useful
marker for cancer progression (Wehler et al, 2006; Kajiyama et al,
2008).
Previous study showed siRNA directed against CXCR4 could
inhibit breast cancer migration in vitro (Liang et al, 2005), but the
influence of CXCR4 knockdown on pancreatic cancer was hardly
known. Considering the important role of CXCR4 in cancer
progression, we designed a CXCR4 shRNA vector as an alternative
to blocking receptor/ligand interaction. To avoid the empty vector
backbone influence, we applied the pRNAT-MN as control cells
instead of Miapaca-2 cells. Our data showed that the plasmid could
effectively inhibit the CXCR4 expression. At the same time, the
phosphorylation of CXCR4 at serine 339 was obviously reduced,
and the proportion of phosphorylated CXCR4 was decreased.
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Figure 4 The influence of CXCR4 knockdown on Wnt target gene and
invasion-related genes. (A) b-Catenin/Tcf transcription reporter assay.
Normalised with control reporter plasmid, the relative luciferase activity
was demonstrated. *Po0.05 compared with pRNAT-MN cells; (B)Q T –
PCR analysis to examine the CTNNB1 (b-catenin), UPA, SLUG, CD44,
MYC(c-MYC), Vim (Vimentin), CCND1 (cyclin D1) gene expression by
the 2 DDCt method. *Po0.05 compared with pRNAT-MN cells; (C)
western blot analysis to detect MMP-9 and Vimentin protein expression.
GAPDH was used as a loading control.
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serine 339 may be a way to express the CXCR4 function on the cells
(Woerner et al, 2005), thus our data further confirmed that CXCR4
shRNA-transfected cells could effectively inhibit CXCR4 function
in pancreatic cancers.
Tumorigenesis is the result of cell cycle disorganisation, leading
to uncontrolled cellular proliferation and cancer progression. In
this study, we demonstrated that the block of CXCR4 could not
only decrease pancreatic cancer cell growth, but also increase sub-
G1 apoptotic compartment, prolong the G0–G1 cycle and reduce
the G2 and S phase. At the same time, it may lower anchorage-
independent growth ability. With the CXCR4 knockdown, cell
growth, cell cycle and cell colony formation ability were inhibited,
so pancreatic cancer cell tumorigenesis was prevented effectively.
Deregulation of Wnt signalling is a well-established hallmark of
certain human cancers, such as colorectal cancer and melanoma
(Ilyas, 2005). Activation of the Wnt target gene will contribute to
the development of cancer in terms of proliferation, invasion and
metastasis, and angiogenesis (Taketo, 2006; Neth et al, 2007).
Additionally, inhibition of Wnt signalling could reduce cell
proliferation and increase apoptosis in pancreatic adenocarcinoma
cells (Miao et al,2 0 0 3 ;P a s c ad iM a g l i a n oet al, 2007; Nawroth et al,
2007). Here, the b-catenin/Tcf assay showed that the TOPflash
luciferase activity was obviously decreased whereas FOPflash
luciferase activity has no change. Moreover, the expression of Wnt
target genes including CTNNB1, CD44, UPA, and MMP-9 were
markedly decreased. Thus, we assumed that the TCF-binding activity
in CXCR4 knockdown cells could be effectively inhibited, which may
influence the Wnt/b-catenin signalling and the Wnt target gene could
not be activated. However, as the canonical Wnt pathway and
b-catenin were regulated by multiple factors together, only blocking
CXCR4 expression could not totally inhibit Wnt pathway.
Next, we evaluated the expression of invasion-related genes –
Vimentin and Slug expression. These two genes are typical
mesenchymal markers associated with the EMT process, influen-
cing carcinoma metastasis (Thiery, 2002; Shioiri et al, 2006). Our
data showed that Vimentin and Slug could be downregulated in
CXCR4 knockdown cells. It is consistent with the study on oral
carcinomas which showed that CXCR4 could influence EMT
formation and cancer invasion (Onoue et al, 2006).
Among the chemokine and chemokine receptors interaction,
SDF-1 was proved to be a stimulator of invasion for CXCR4-
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Figure 5 The abrogation of CXCR4 inhibits the invasive potential ability of pancreatic cancer cells.  200; (A) representative staining figure: pRNAT-MN
invading cells without SDF-1 stimulation (a), pRNAT-MN invading cells with 100ngml
 1 SDF-1 stimulation (b), pRNAT-M1 invading cells without SDF-1
stimulation (c), pRNAT-M1 invading cells with 100ngml
 1 SDF-1 stimulation (d); (B) the diagram of the count analysis, *Po0.05 compared with pRNAT-
MN cells.
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the effect of CXCR4 shRNA on metastasis was related to pancreatic
cancer in vitro, we conducted the Matrigel chamber invasion assay.
Our data showed under normal conditions, the invasive ability of
CXCR4-transfected cancer cells was inhibited compared with the
control cells. Moreover, much more difference was observed
between control cells and CXCR4 knockdown cells after SDF-1
stimulation. However, we also found that as there was 70%
inhibition of CXCR4 through shRNA, the invasive ability could not
be totally blocked.
CXCR4 was a promising marker for pancreatic cancer progres-
sion. The CXCR4-positive expression was considered to be
associated with a poor clinical outcome. Moreover, the abrogation
of CXCR4 could influence the pancreatic cancer cell phenotype
including cell proliferation, colony formation, and cell invasion
through the inhibition of canonical Wnt pathway. Given the
important role that CXCR4 plays in the process of pancreatic
cancer progression, CXCR4 is a very intriguing therapeutic target.
Understanding the precise mechanisms of CXCR4 function should
provide insight into attractive pancreatic cancer therapy.
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